Modulators of cystic fibrosis transmembrane conductance regulator
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.
1. A compound of Formula (1):
or a pharmaceutically acceptable salt or deuterated derivative thereof, wherein:
X is selected from Si(R) 3 , —(O) n —(C 1 -C 8 alkyl), —(O) n —(C 3 -C 10 cycloalkyl), wherein:
n is 0 or 1,
each C 1 -C 8 alkyl is substituted with 0, 1, 2, or 3 groups selected from halogen, hydroxy, oxo, C 3 -C 10 cycloalkyl, C 1 -C 4 haloalkyl, and Si(R) 3 groups,
each C 3 -C 10 cycloalkyl is substituted with 0, 1, 2, 3, or 4 groups selected from halogen, C 1 -C 4 haloalkyl, C 1 -C 4 alkyl, and Si(R) 3 groups, and one —CH 2 - in each C 1 -C 8 alkyl is optionally replaced with —Si(R) 2 —;
Y is selected from hydrogen and —Si(R) 3 ;
each Z is independently selected from —CH 2 — and —Si(R) 2 —; and
each R is independently selected from phenyl and C 1 -C 6 alkyl groups; and
wherein the compound of Formula (1) contains at least one Si atom.
2. The compound of claim 1 , wherein X is selected from Si(R) 3 ,
3. The compound of claim 1 , wherein the compound is chosen from:
and pharmaceutically acceptable salts and deuterated derivatives thereof.
4. The compound of claim 1 , wherein at least one hydrogen is replaced by deuterium.
5. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt.
6. A compound of Formula (2):
or a pharmaceutically acceptable salt or deuterated derivative thereof, wherein:
X is selected from Ge(R) 3 , —(O) n —(C 1 -C 8 alkyl), —(O) n —(C 3 -C 10 cycloalkyl), wherein:
n is 0 or 1,
each C 1 -C 8 alkyl is substituted with 0, 1, 2, or 3 groups selected from halogen, hydroxy, oxo, C 3 -C 10 cycloalkyl, C 1 -C 4 haloalkyl, and Ge(R) 3 groups, each C 3 -C 10 cycloalkyl is substituted with 0, 1, 2, 3, or 4 groups selected from halogen, C 1 -C 4 haloalkyl, C 1 -C 4 alkyl, and Ge(R) 3 groups, and one —CH 2 — in each C 1 -C 8 alkyl is optionally replaced with —Ge(R) 2 —;
Y is selected from hydrogen and —Ge(R) 3 ;
each Z is independently selected from —CH 2 — and —Ge(R) 2 —; and
each R is independently selected from phenyl and C 1 -C 6 alkyl groups; and
wherein the compound of Formula (2) contains at least one Ge atom.
7. The compound of claim 6 , wherein X is selected from Ge(R) 3 ,
8. The compound of claim 6 , wherein the compound is chosen from:
and pharmaceutically acceptable salts and deuterated derivatives thereof.
9. The compound of claim 6 , wherein at least one hydrogen is replaced by deuterium.
10. The compound of claim 6 , wherein the compound is a pharmaceutically acceptable salt.
11. A compound of Formula (3):
or a pharmaceutically acceptable salt or deuterated derivative thereof, wherein:
the carbon atom at position 2 of Formula (3) is replaced by a silicon atom;
at least one of the methyl groups at positions 6 and 7 of Formula (3) is replaced by a group chosen from —Si(R) 3 groups, —Si(R) 2 (OR) groups, and —Si(R)(OR) 2 groups;
at least one of the methylene groups at positions 3, 5, and 8 of Formula (3) is replaced by a group chosen from >Si(R) 2 groups and >Si(R)(OR) groups; and/or
the methine group at position 4 of Formula (3) is replaced by a group chosen from ≡Si(R) groups and ≡Si(OR) groups; and
wherein each R is independently chosen from hydrogen, phenyl, and C 1 -C 6 alkyl groups.
12. The compound of claim 11 , wherein at least one hydrogen is replaced by deuterium.
13. The compound of claim 11 , wherein the compound is a pharmaceutically acceptable salt.
14. A compound of Formula (4):
or a pharmaceutically acceptable salt or deuterated derivative thereof, wherein:
the carbon atom at position 2 of Formula (4) is replaced by a germanium atom;
at least one of the methyl groups at positions 6 and 7 of Formula (4) is replaced by a group chosen from —Ge(R) 3 groups, —Ge(R) 2 (OR) groups, and —Ge(R)(OR) 2 groups;
at least one of the methylene groups at positions 3, 5, and 8 of Formula (4) is replaced by a group chosen from >Ge(R) 2 groups and >Ge(R)(OR) groups; and/or
the methine group at position 4 of Formula (4) is replaced by a group chosen from ≡Ge(R) groups and ≡Ge(OR) groups; and
wherein each R is independently chosen from hydrogen, phenyl, and C 1 -C 6 alkyl groups.
15. The compound of claim 14 , wherein at least one hydrogen is replaced by deuterium.
16. The compound of claim 14 , wherein the compound is a pharmaceutically acceptable salt.
17. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
18. The pharmaceutical composition of claim 17 , further comprising one or more additional therapeutic agent(s).
19. The pharmaceutical composition of claim 18 , wherein the one or more additional therapeutic agent(s) comprise(s) a compound selected from:
and
(d) pharmaceutically acceptable salts thereof.
20. The pharmaceutical composition of claim 19 , wherein the composition comprises Compound II and Compound III.
21. The pharmaceutical composition of claim 19 , wherein the composition comprises Compound II and Compound III-d.
22. A pharmaceutical composition comprising:
(a) at least one compound chosen from compounds of claim 1 ;
(b) at least one pharmaceutically acceptable carrier; and
optionally one or more of:
(c) (i) a compound chosen from Compound II:
and pharmaceutically acceptable salts and deuterated derivatives thereof; and
(ii) a compound chosen from Compound III, Compound III-d:
and pharmaceutically acceptable salts and deuterated derivatives thereof.
23. A method of treating cystic fibrosis comprising administering to a patient in need thereof a compound of claim 1 .
24. The method of claim 23 , further comprising administering to the patient one or more additional therapeutic agent(s) prior to, concurrent with, or subsequent to the compound.
25. The method of claim 24 , wherein the one or more additional therapeutic agent(s) comprise(s) a compound selected from:
and
(d) pharmaceutically acceptable salts thereof.
26. The method of claim 25 , wherein the one or more additional therapeutic agent(s) comprise(s) Compound II and Compound III.
27. The method of claim 25 , wherein the one or more additional therapeutic agent(s) comprise(s) Compound II and Compound III-d.